메뉴 건너뛰기




Volumn 5, Issue 2, 2014, Pages 459-469

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

Author keywords

Dipeptidyl peptidase 4; Hypoglycemia; Sulfonylurea; Type 2 diabetes; Vildagliptin

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN;

EID: 84919650730     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0082-y     Document Type: Article
Times cited : (12)

References (29)
  • 1
    • 33748366186 scopus 로고    scopus 로고
    • Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management
    • Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes. 2006;24:115–21.
    • (2006) Clin Diabetes , vol.24 , pp. 115-121
    • Briscoe, V.J.1    Davis, S.N.2
  • 2
    • 84903156652 scopus 로고    scopus 로고
    • Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia
    • PID: 24962915
    • Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes. 2014;63:2188–95.
    • (2014) Diabetes , vol.63 , pp. 2188-2195
    • Cryer, P.E.1
  • 3
    • 0036020278 scopus 로고    scopus 로고
    • Hypoglycemia: the limiting factor in the glycemic management of type I and type II diabetes
    • COI: 1:CAS:528:DC%2BD38XltlOntr0%3D, PID: 12136392
    • Cryer PE. Hypoglycemia: the limiting factor in the glycemic management of type I and type II diabetes. Diabetologia. 2002;45:937–48.
    • (2002) Diabetologia , vol.45 , pp. 937-948
    • Cryer, P.E.1
  • 4
    • 78649713954 scopus 로고    scopus 로고
    • Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience
    • COI: 1:CAS:528:DC%2BC3cXos12ntbo%3D, PID: 20730070
    • Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–8.
    • (2010) Vasc Health Risk Manag , vol.6 , pp. 541-548
    • Foley, J.E.1    Jordan, J.2
  • 5
    • 77952516258 scopus 로고    scopus 로고
    • Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy
    • COI: 1:CAS:528:DC%2BC3cXmtFagtLY%3D, PID: 20370379
    • Barnett AH. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Curr Med Res Opin. 2010;26:1333–42.
    • (2010) Curr Med Res Opin , vol.26 , pp. 1333-1342
    • Barnett, A.H.1
  • 6
    • 74949117631 scopus 로고    scopus 로고
    • The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
    • PID: 20061358
    • Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
    • (2010) BMJ , vol.340 , pp. b4909
    • Bonds, D.E.1    Miller, M.E.2    Bergenstal, R.M.3    Buse, J.B.4    Byington, R.P.5    Cutler, J.A.6
  • 7
    • 77952038062 scopus 로고    scopus 로고
    • Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model
    • COI: 1:STN:280:DC%2BC3c3os1yqsw%3D%3D, PID: 20415691
    • McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010;12:431–6.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 431-436
    • McEwan, P.1    Evans, M.2    Kan, H.3    Bergenheim, K.4
  • 8
    • 33646252953 scopus 로고    scopus 로고
    • Cost of hypoglycemia in patients with type 2 diabetes in Sweden
    • PID: 16689714
    • Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health. 2006;9:193–8.
    • (2006) Value Health , vol.9 , pp. 193-198
    • Jönsson, L.1    Bolinder, B.2    Lundkvist, J.3
  • 10
    • 65249095686 scopus 로고    scopus 로고
    • Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes
    • PID: 19174497
    • Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1236–43.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 1236-1243
    • Ahrén, B.1    Schweizer, A.2    Dejager, S.3    Dunning, B.E.4    Nilsson, P.M.5    Persson, M.6
  • 11
    • 84905725690 scopus 로고    scopus 로고
    • Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes
    • COI: 1:CAS:528:DC%2BC2cXhtlKjtL%2FE, PID: 24612221
    • Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:812–8.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 812-818
    • Farngren, J.1    Persson, M.2    Schweizer, A.3    Foley, J.E.4    Ahrén, B.5
  • 12
    • 82255185915 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
    • COI: 1:CAS:528:DC%2BC38XpvFOisA%3D%3D, PID: 21984584
    • Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60:3103–9.
    • (2011) Diabetes , vol.60 , pp. 3103-3109
    • Christensen, M.1    Vedtofte, L.2    Holst, J.J.3    Vilsbøll, T.4    Knop, F.K.5
  • 13
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • COI: 1:CAS:528:DC%2BD1MXivVWjtLk%3D, PID: 19125777
    • Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157–66.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3    Matthews, D.4    Ahrén, B.5    Byiers, S.6
  • 14
    • 77955048324 scopus 로고    scopus 로고
    • Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
    • COI: 1:CAS:528:DC%2BC3cXhtFGntbnP, PID: 20649630
    • Matthews DR, Dejager S, Ahrén B, Fonseca V, Ferrannini E, Couturier A, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12:780–9.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 780-789
    • Matthews, D.R.1    Dejager, S.2    Ahrén, B.3    Fonseca, V.4    Ferrannini, E.5    Couturier, A.6
  • 15
    • 21844494977 scopus 로고
    • It’s Déjà Vu all over again: using multiple-spell discrete time survival analysis
    • Willet JB, Singer JD. It’s Déjà Vu all over again: using multiple-spell discrete time survival analysis. J Educ Behav Stat. 1995;20:41–67.
    • (1995) J Educ Behav Stat , vol.20 , pp. 41-67
    • Willet, J.B.1    Singer, J.D.2
  • 16
    • 84864558772 scopus 로고    scopus 로고
    • Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1c value
    • COI: 1:CAS:528:DC%2BC38XhtFCrsLjI, PID: 22697277
    • Krobot KJ, Ferrante SA, Davies MJ, Seck T, Meininger GE, Williams-Herman D, et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1c value. Curr Med Res Opin. 2012;28:1281–7.
    • (2012) Curr Med Res Opin , vol.28 , pp. 1281-1287
    • Krobot, K.J.1    Ferrante, S.A.2    Davies, M.J.3    Seck, T.4    Meininger, G.E.5    Williams-Herman, D.6
  • 17
    • 0021263283 scopus 로고
    • Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions
    • COI: 1:CAS:528:DyaL2cXksVyqu7g%3D, PID: 6373827
    • Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest. 1984;73:1532–41.
    • (1984) J Clin Invest , vol.73 , pp. 1532-1541
    • Bolli, G.B.1    Tsalikian, E.2    Haymond, M.W.3    Cryer, P.E.4    Gerich, J.E.5
  • 18
    • 0034853485 scopus 로고    scopus 로고
    • Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes
    • COI: 1:CAS:528:DC%2BD3MXmvFCktrY%3D, PID: 11549624
    • Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047–58.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 4047-4058
    • Kahn, S.E.1
  • 19
    • 84908614109 scopus 로고    scopus 로고
    • β-Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes
    • Michaliszyn SF, Mari A, Lee S, Bacha F, Tfayli H, Farchoukh L, et al. β-Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes 2014 [Epub ahead of print].
    • (2014) Diabetes
    • Michaliszyn, S.F.1    Mari, A.2    Lee, B.3    Bacha, F.4    Tfayli, H.5    Farchoukh, L.6
  • 20
    • 0035216023 scopus 로고    scopus 로고
    • Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus
    • COI: 1:CAS:528:DC%2BD3MXptVylu7g%3D, PID: 11739446
    • Kahn SE, Montgomery B, Howell W, Ligueros-Saylan M, Hsu CH, Devineni D, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2001;86:5824–9.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 5824-5829
    • Kahn, S.E.1    Montgomery, B.2    Howell, W.3    Ligueros-Saylan, M.4    Hsu, C.H.5    Devineni, D.6
  • 21
    • 18144419321 scopus 로고    scopus 로고
    • Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide
    • COI: 1:CAS:528:DC%2BD2MXksF2hu7c%3D, PID: 15855578
    • Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care. 2005;28:1132–8.
    • (2005) Diabetes Care , vol.28 , pp. 1132-1138
    • Mari, A.1    Gastaldelli, A.2    Foley, J.E.3    Pratley, R.E.4    Ferrannini, E.5
  • 22
    • 4344693381 scopus 로고    scopus 로고
    • GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
    • COI: 1:CAS:528:DC%2BD2cXnslOhtrk%3D, PID: 15305887
    • Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34:535–42.
    • (2004) Eur J Clin Invest , vol.34 , pp. 535-542
    • Schernthaner, G.1    Grimaldi, A.2    Di Mario, U.3    Drzewoski, J.4    Kempler, P.5    Kvapil, M.6
  • 23
    • 0021918189 scopus 로고
    • Pathogenesis of impaired glucose tolerance and type II diabetes mellitus––current status
    • COI: 1:STN:280:DyaL2M3ks1CktA%3D%3D, PID: 3892914
    • Davidson MB. Pathogenesis of impaired glucose tolerance and type II diabetes mellitus––current status. West J Med. 1985;142:219–29.
    • (1985) West J Med , vol.142 , pp. 219-229
    • Davidson, M.B.1
  • 24
    • 13644263258 scopus 로고    scopus 로고
    • Oral antidiabetic agents: current role in type 2 diabetes mellitus
    • COI: 1:CAS:528:DC%2BD2MXit1Grsbg%3D, PID: 15669880
    • Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411.
    • (2005) Drugs , vol.65 , pp. 385-411
    • Krentz, A.J.1    Bailey, C.J.2
  • 25
    • 0033304547 scopus 로고    scopus 로고
    • Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes
    • COI: 1:CAS:528:DyaK1MXlvVGksLs%3D, PID: 10487677
    • Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84:3140–5.
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 3140-3145
    • Landstedt-Hallin, L.1    Adamson, U.2    Lins, P.E.3
  • 26
    • 0030971354 scopus 로고    scopus 로고
    • The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans
    • COI: 1:CAS:528:DyaK2sXjtVGmurY%3D, PID: 9141533
    • Peacey SR, Rostami-Hodjegan A, George E, Tucker GT, Heller SR. The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. J Clin Endocrinol Metab. 1997;82:1458–61.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 1458-1461
    • Peacey, S.R.1    Rostami-Hodjegan, A.2    George, E.3    Tucker, G.T.4    Heller, S.R.5
  • 27
    • 84867238377 scopus 로고    scopus 로고
    • Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes
    • COI: 1:CAS:528:DC%2BC38XhsFKkurfN, PID: 22855332
    • Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97:3799–806.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 3799-3806
    • Farngren, J.1    Persson, M.2    Schweizer, A.3    Foley, J.E.4    Ahrén, B.5
  • 28
    • 84879186130 scopus 로고    scopus 로고
    • Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
    • COI: 1:CAS:528:DC%2BC3sXjsFShsb0%3D, PID: 23431062
    • Schweizer A, Foley JE, Kothny W, Ahrén B. Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin. Vasc Health Risk Manag. 2013;9:57–64.
    • (2013) Vasc Health Risk Manag , vol.9 , pp. 57-64
    • Schweizer, A.1    Foley, J.E.2    Kothny, W.3    Ahrén, B.4
  • 29
    • 84865658472 scopus 로고    scopus 로고
    • Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
    • COI: 1:CAS:528:DC%2BC38XotVyrurg%3D, PID: 22661900
    • Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339–48.
    • (2012) Vasc Health Risk Manag , vol.8 , pp. 339-348
    • Dejager, S.1    Schweizer, A.2    Foley, J.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.